New prices for generic equivalent drugs

2011 ◽  
Vol 12 (1) ◽  
pp. 3-4
Author(s):  
Ombretta Bandi
Keyword(s):  
Generic Equivalent

Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model

2016 ◽  
Vol 141 (2) ◽  
pp. 357-363 ◽  
Author(s):  
Judith A. Smith ◽  
Lata Mathew ◽  
Maryam Burney ◽  
Pranavanand Nyshadham ◽  
Robert L. Coleman
Keyword(s):  
Ovarian Cancer ◽  
Mouse Model ◽  
Human Ovarian Cancer ◽  
Generic Equivalent

scholarly journals Generic - equivalent drugs use in internal and general medicine patients: distrust, confusion, lack of certainties or knowledge? Part 1. Pharmacological issues

2014 ◽  
Vol 8 (2) ◽  
pp. 80 ◽  
Author(s):  
Roberto Nardi ◽  
Marco Masina ◽  
Giorgio Cioni ◽  
Paolo Leandri ◽  
Paola Zuccheri
Keyword(s):  
General Medicine ◽  
Generic Equivalent

Innovator Vancomycin Outperforms Its Generic “Equivalent”

2010 ◽  
Vol 5 (10) ◽  
pp. 419-420
Author(s):  
David C. Holzman
Keyword(s):  
Generic Equivalent

scholarly journals Wixela Inhub: A Generic Equivalent Treatment Option for Patients with Asthma or COPD

2020 ◽  
Author(s):  
James F. Donohue ◽  
Douglas S. Burgoyne ◽  
Jonathan K. Ward ◽  
Richard Allan ◽  
Arkady Koltun ◽  
...  
Keyword(s):  
Treatment Option ◽  
Generic Equivalent

scholarly journals Comparison of the efficacy and safety of CELBESTA® versus CELEBREX® in patients with rheumatoid arthritis: a 6-week, multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority phase 4 clinical trial

2020 ◽  
Vol 48 (6) ◽  
pp. 030006052093132
Author(s):  
Hyun-Sook Kim ◽  
Won-Ho Choi ◽  
Bo Young Kim ◽  
Sung Soo Kim ◽  
Sang-Il Lee ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Trial ◽  
Renal Toxicity ◽  
Least Square ◽  
Efficacy And Safety ◽  
Generic Equivalent ◽  
Analog Scale ◽  
Double Blind ◽  
Parallel Group ◽  
The Difference

Objectives Celecoxib is a selective cyclooxygenase (COX)-2 inhibitor that is commonly used to reduce the incidence of gastrointestinal (GI) complications in patients with rheumatoid arthritis (RA). CELBESTA® is a generic equivalent to CELEBREX®, a celecoxib preparation. This study compared the efficacy and safety of CELBESTA® and CELEBREX® in patients with RA. Methods This was a multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority clinical trial. The primary endpoint was a change from baseline in self-assessed pain intensity determined using a 100-mm visual analog scale after 6 weeks of treatment. Results After a washout period, 119 eligible subjects were randomized to one of two groups (CELBESTA® group, n = 61; CELEBREX® group, n = 58). CELBESTA® was not inferior to CELEBREX® because the upper limit of two-sided 95% confidence interval (CI) for the difference between the two groups (difference in the least square [LS] mean, −8.68 mm; two-sided 95% CI −16.59 mm to −0.77 mm) was less than the non-inferiority margin (10 mm). There were no significant differences in GI complications and renal toxicity. Conclusions CELBESTA® was not inferior to CELEBREX® with regard to the pain relief efficacy in RA patients, and the tolerability and safety profiles were excellent and at similar levels for both preparations.

Sign in / Sign up

Export Citation Format

Share Document